Insider Trade: Aerie Pharmaceuticals, Inc. (AERI)’s Chief Executive Officer Vicente Anido Unloaded 150,000 shares; 7 Bullish Analysts Covering Xencor, Inc. (XNCR)

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Among 9 analysts covering Xencor (NASDAQ:XNCR), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Xencor had 25 analyst reports since August 5, 2015 according to SRatingsIntel. On Monday, November 13 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Thursday, April 26. The stock of Xencor, Inc. (NASDAQ:XNCR) earned “Overweight” rating by Piper Jaffray on Tuesday, October 4. As per Saturday, August 8, the company rating was downgraded by Zacks. The company was maintained on Wednesday, February 28 by Piper Jaffray. The company was maintained on Thursday, March 29 by Cantor Fitzgerald. The stock of Xencor, Inc. (NASDAQ:XNCR) has “Buy” rating given on Sunday, November 12 by Piper Jaffray. Cantor Fitzgerald maintained Xencor, Inc. (NASDAQ:XNCR) rating on Tuesday, May 8. Cantor Fitzgerald has “Buy” rating and $3700 target. Cantor Fitzgerald initiated the shares of XNCR in report on Tuesday, November 28 with “Buy” rating. The stock of Xencor, Inc. (NASDAQ:XNCR) earned “Hold” rating by Zacks on Friday, September 4. See Xencor, Inc. (NASDAQ:XNCR) latest ratings:

07/06/2018 Broker: BTIG Research Rating: Buy New Target: $56 Initiates Coverage On
09/05/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $36 New Target: $38 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0000 Maintain
26/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $46.0000 Maintain
05/04/2018 Broker: Nomura Rating: Hold New Target: $28.0000
29/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0000 Maintain
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $36.0000 Initiate
26/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $46.0000 Maintain
19/03/2018 Broker: Wedbush Rating: Outperform Old Target: $38 New Target: $39 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $40.0 Maintain

At an average stock price per share of $62.3, Vicente Anido, the Aerie Pharmaceuticals Inc’s Chief Executive Officer unloaded 150,000 shares of Aerie Pharmaceuticals Inc worth approx. $9,342,381 US Dollars. The probability that this trade stays undiscovered is super low owing to the large amount of money involved. Currently, Vicente Anido owns 126,320 shares which are equivalent to roughly 0.32% of the company’s market capitalization (total value of the shares outstanding).

The stock decreased 2.92% or $1.9 during the last trading session, reaching $63.25. About 611,257 shares traded or 82.51% up from the average. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has declined 8.48% since June 10, 2017 and is downtrending. It has underperformed by 21.05% the S&P500. Some Historical AERI News: ; 30/05/2018 – Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management; 12/04/2018 – Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™; 01/05/2018 – Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel; 15/05/2018 – Healthcor Management Buys New 3% Position in Aerie; 08/05/2018 – Aerie Pharmaceuticals 1Q Loss $40.7M; 05/04/2018 – Aerie at Non-Deal Roadshow Hosted By Seaport Today; 21/03/2018 – Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan’s Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu B; 15/05/2018 – AERIE PHARMACEUTICALS – EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS; 07/05/2018 – Aerie Non-Deal Roadshow Scheduled By JMP Securities for May. 14; 30/04/2018 – AERIE PHARMACEUTICALS REPORTS U.S. LAUNCH OF RHOPRESSA 0.02%

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.50 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on August, 7. They expect $-0.96 EPS, down 17.07% or $0.14 from last year’s $-0.82 per share. After $-1.05 actual EPS reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.57% EPS growth.

More news for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were recently published by:, which released: “Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference” on May 31, 2018.‘s article titled: “Aerie Pharma (AERI): Early Physician Rhopressa Feedback is Cautiously Positive – Cowen” and published on May 24, 2018 is yet another important article.

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals has $10000 highest and $30 lowest target. $74.15’s average target is 17.23% above currents $63.25 stock price. Aerie Pharmaceuticals had 53 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Strong Buy” rating given on Wednesday, September 14 by Raymond James. The company was maintained on Monday, October 16 by Canaccord Genuity. As per Wednesday, October 11, the company rating was maintained by Cantor Fitzgerald. H.C. Wainwright maintained the shares of AERI in report on Wednesday, August 2 with “Buy” rating. The firm earned “Market Outperform” rating on Wednesday, September 9 by JMP Securities. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Outperform” rating given on Friday, October 28 by RBC Capital Markets. H.C. Wainwright maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Wednesday, May 9. H.C. Wainwright has “Buy” rating and $7800 target. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by JMP Securities on Friday, September 22. The firm has “Buy” rating given on Thursday, November 9 by Cowen & Co. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Tuesday, September 20 by H.C. Wainwright.

Since May 21, 2018, it had 2 buys, and 1 sale for $36,111 activity. The insider Cagle Gerald D. bought $50,245. On Thursday, May 24 Kopczynski Casey C. sold $135,806 worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 2,708 shares.

Investors sentiment decreased to 1.19 in Q1 2018. Its down 0.01, from 1.2 in 2017Q4. It turned negative, as 18 investors sold Aerie Pharmaceuticals, Inc. shares while 46 reduced holdings. 17 funds opened positions while 59 raised stakes. 39.43 million shares or 13.11% more from 34.86 million shares in 2017Q4 were reported. Fmr Limited Liability has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Geode Cap Mngmt Ltd Liability Corporation invested in 0.01% or 338,677 shares. Pictet Asset Mngmt Limited invested 0.07% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). State Board Of Administration Of Florida Retirement Sys invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Zurcher Kantonalbank (Zurich Cantonalbank) owns 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 1,681 shares. 32,875 were reported by Royal Fincl Bank Of Canada. Endurance Wealth Mngmt Inc reported 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Aqr Management Lc invested in 11,317 shares. Weiss Multi stated it has 45,000 shares or 0.08% of all its holdings. Teachers Retirement Sys Of The State Of Kentucky invested in 63,220 shares or 0.04% of the stock. Us Savings Bank De accumulated 932 shares. Boulegeris Invs has 65,865 shares for 1.96% of their portfolio. Baker Bros Advsrs L P holds 215,655 shares. Platinum Investment Mngmt stated it has 37,600 shares or 0.06% of all its holdings. Aperio Grp Ltd holds 0% or 5,642 shares.

The stock increased 2.27% or $0.94 during the last trading session, reaching $42.41. About 268,240 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 82.34% since June 10, 2017 and is uptrending. It has outperformed by 69.77% the S&P500. Some Historical XNCR News: ; 18/04/2018 – Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer; 07/05/2018 – Xencor 1Q Rev $0.00; 10/04/2018 – Xencor Presenting at Deutsche Bank Health Care Conference May 9; 07/05/2018 – XENCOR INC – EXPECTS TO END 2018 WITH APPROXIMATELY $500 MLN IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES; 07/05/2018 – XENCOR INC – EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2023; 20/03/2018 – Xencor Announces Pricing of Public Offering of Common Stk; 18/04/2018 – Applied BioMath, LLC Collaborates with Xencor for Semi-Mechanistic PK/PD Modeling of XmAb®24306, Xencor’s Lead IL15 Program fo; 07/05/2018 – Xencor 1Q Loss/Shr 62c; 20/03/2018 – XENCOR REPORTS OFFERING PRICES AT $31.00/SHR; 08/05/2018 – Xencor Closes Below 50-Day Moving Average: Technicals

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $2.36 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Investors sentiment increased to 1.7 in Q1 2018. Its up 0.49, from 1.21 in 2017Q4. It increased, as 7 investors sold Xencor, Inc. shares while 30 reduced holdings. 28 funds opened positions while 35 raised stakes. 43.81 million shares or 19.94% more from 36.52 million shares in 2017Q4 were reported. Guggenheim Limited Liability Corporation holds 0% or 7,683 shares in its portfolio. Moreover, Retail Bank Of New York Mellon has 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 178,333 shares. D E Shaw Inc invested in 0% or 23,862 shares. Voya Invest Mgmt Ltd Company reported 16,793 shares. Rhumbline Advisers invested in 0% or 35,430 shares. Sg Americas Secs Limited Liability Company stated it has 3,848 shares. Td Asset reported 115,044 shares or 0.01% of all its holdings. Fmr Limited Liability holds 8.15 million shares. Pub Employees Retirement Association Of Colorado reported 0% stake. Mufg Americas holds 471 shares. Moreover, Price T Rowe Associate Md has 0.03% invested in Xencor, Inc. (NASDAQ:XNCR). Dimensional Fund Advsrs Limited Partnership reported 254,019 shares. Moreover, Los Angeles Capital Mngmt And Equity Research Inc has 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 10,620 shares. Cannell Peter B Com Inc holds 0.26% of its portfolio in Xencor, Inc. (NASDAQ:XNCR) for 228,750 shares. Barclays Public Limited holds 8,960 shares.

More important recent Xencor, Inc. (NASDAQ:XNCR) news were published by: which released: “Premarket analyst action – healthcare” on June 07, 2018, also published article titled: “BTIG Starts Xencor, Inc. (XNCR) at Buy”, published: “Benzinga’s Top Upgrades, Downgrades For June 7, 2018” on June 07, 2018. More interesting news about Xencor, Inc. (NASDAQ:XNCR) was released by: and their article: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” with publication date: May 25, 2018.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart